Bifeprunox

Experimental dopamine D2 receptor partial agonist researched as an antipsychotic agent
  • none
Identifiers
  • 7-[4-(biphenyl-3-ylmethyl)piperazin-1-yl]-1,3-benzoxazol-2(3H)-one
CAS Number
  • 350992-10-8 ☒N
PubChem CID
  • 208951
ChemSpider
  • 181044 checkY
UNII
  • AP69E83Z79
ChEMBL
  • ChEMBL218166 checkY
CompTox Dashboard (EPA)
  • DTXSID80188592 Edit this at Wikidata
Chemical and physical dataFormulaC24H23N3O2Molar mass385.467 g·mol−13D model (JSmol)
  • Interactive image
  • O=C2Oc1c(cccc1N2)N5CCN(Cc4cccc(c3ccccc3)c4)CC5
InChI
  • InChI=1S/C24H23N3O2/c28-24-25-21-10-5-11-22(23(21)29-24)27-14-12-26(13-15-27)17-18-6-4-9-20(16-18)19-7-2-1-3-8-19/h1-11,16H,12-15,17H2,(H,25,28) checkY
  • Key:CYGODHVAJQTCBG-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Bifeprunox (INN) (code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D2 receptor agonism with serotonin receptor agonism.[1] It was under development for the treatment of schizophrenia, psychosis and Parkinson's disease.[2]

In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects.[3]An NDA for Bifeprunox was filed with the U.S. Food and Drug Administration in January 2007. The FDA rejected the application in August 2007.[4] In June 2009, Solvay and Wyeth decided to cease development because "efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia."[5]

Pharmacodynamics

Bifeprunox is an atypical antipsychotic that is a partial D2 agonist.

See also

  • Aripiprazole
  • Pardoprunox

References

  1. ^ Cuisiat S, Bourdiol N, Lacharme V, Newman-Tancredi A, Colpaert F, Vacher B (2007). "Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities". J. Med. Chem. 50 (4): 865–76. doi:10.1021/jm061180b. PMID 17300168.
  2. ^ "Bifeprunox". go.drugbank.com. Retrieved 2023-11-16.
  3. ^ Casey DE, Sands EE, Heisterberg J, Yang HM (October 2008). "Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study". Psychopharmacology. 200 (3): 317–31. doi:10.1007/s00213-008-1207-7. PMID 18597078. S2CID 23291727.
  4. ^ Wyeth and Solvay say FDA rejects application for antipsychotic drug bifeprunox. Thomson Financial, August 10, 2007.
  5. ^ Pipeline update - following an interim analysis the studies with bifeprunox for the treatment of schizophrenia is discontinued Archived 2011-07-14 at the Wayback Machine Lundbeck Press Release.
  • v
  • t
  • e
Typical
DisputedAtypicalOthers
  • v
  • t
  • e
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
  • See also: Receptor/signaling modulators
  • Adrenergics
  • Serotonergics
  • Monoamine reuptake inhibitors
  • Monoamine releasing agents
  • Monoamine metabolism modulators
  • Monoamine neurotoxins
  • v
  • t
  • e
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT3–7
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
  • See also: Receptor/signaling modulators
  • Adrenergics
  • Dopaminergics
  • Melatonergics
  • Monoamine reuptake inhibitors and releasing agents
  • Monoamine metabolism modulators
  • Monoamine neurotoxins
  • v
  • t
  • e
Simple piperazines
(no additional rings)
Phenylpiperazines
Benzylpiperazines
Diphenylalkylpiperazines
(benzhydrylalkylpiperazines)
Pyrimidinylpiperazines
Pyridinylpiperazines
Benzo(iso)thiazolylpiperazines
Tricyclics
(piperazine attached via side chain)
Others/Uncategorized